CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Holdings Decreased by Stifel Financial Corp

Stifel Financial Corp decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 20.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,237 shares of the company’s stock after selling 10,175 shares during the period. Stifel Financial Corp’s holdings in CRISPR Therapeutics were worth $1,890,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of CRSP. Readystate Asset Management LP bought a new position in shares of CRISPR Therapeutics in the third quarter worth $336,000. Reynders McVeigh Capital Management LLC boosted its position in shares of CRISPR Therapeutics by 4.3% in the third quarter. Reynders McVeigh Capital Management LLC now owns 119,586 shares of the company’s stock worth $5,618,000 after buying an additional 4,913 shares during the period. Benjamin Edwards Inc. grew its position in CRISPR Therapeutics by 13,640.8% during the third quarter. Benjamin Edwards Inc. now owns 32,703 shares of the company’s stock valued at $1,536,000 after purchasing an additional 32,465 shares in the last quarter. Baker BROS. Advisors LP grew its stake in CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of CRISPR Therapeutics by 32.0% during the 3rd quarter. Captrust Financial Advisors now owns 31,712 shares of the company’s stock worth $1,490,000 after purchasing an additional 7,688 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on CRSP shares. Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average target price of $77.93.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $40.72 on Friday. The stock’s 50-day simple moving average is $48.45 and its 200 day simple moving average is $50.78. CRISPR Therapeutics AG has a 52-week low of $39.41 and a 52-week high of $91.10. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -14.39 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm posted ($1.41) earnings per share. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,382 shares of company stock valued at $2,744,179. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.